We are excited to announce that Singh Lab is moving from Cornell University to the Georgia Institute of Technology in early 2020. We are actively recruiting talented postdocs, Ph.D. students, MS students, and undergraduate researchers. If interested, visit open positions in the lab.
Our research effort centers on creating functional “living” immune tissues as organoids or on-chip to recapitulate selective aspects of lymph nodes. The engineered tissues communicate dynamically with immune cells (B and T cells) and regulate the fate of immune response. Using engineering principles, we study how various cellular and biophysical components of lymphoid tissues interact with immune cells, their tumors, and how immune cells undergo decision making at the cellular, molecular, and epigenetic levels to protect humans from bacterial and viral infections, cancer, and inflammatory diseases. Our research has led to new discoveries in the field of B cell immunity, derived cancers, and has led to the advancement of new immune therapeutics.
We have four major directions:
- Multiscale engineering of immune cells and lymphoid organs: Our interest is in developing ex vivo immune organoids and on-chip technologies to understand the process through which the B and T cells interact in the immune system to makes antibodies. We are interested in multiscale engineering strategies for the design and development of B and T cell-based immunotherapies. The engineered ex vivo immune organs have applications in immunity, cancer, infections, and inflammation.
- Cancer Bioengineering: Our interest is in understanding how disruption of normal signaling and epigenetic processes results in the transformation of healthy cells to cancers. By developing ex vivo “malignant” tissues in a dish or on-chip, we have led to the discovery and advancement of new classes of signaling, epigenetic, and immune therapeutics. Our focus areas are immune neoplasms, hematological malignancies, and prostate cancer.
- Immunomodulation in Metabolic Syndrome and Gut Microbiome: We are interested in studying the effect of metabolic syndrome on the bioengineered system and develop new immuno-modulatory biomaterials, especially individually tailored nanomedicines to adjust specific microbial species and immune cells in metabolic disorders and inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn’s disease.
- Immunology: We are interested in the study of mechanisms through which the signaling and epigenome programs the normal and disease-specific immune responses.
Research in Singh laboratory is supported by the National Institute of Health (The NIAID; NCI, and NIBIB), Department of Defense, National Science Foundation, 3M, Leukemia and Lymphoma Society, NCI Prostate Cancer SPORE, WCM-CU Seed, and Cornell Animal Health Center.